Guangdong Hengrui Pharmaceutical Co., Ltd

This Phase 1 study tested a single injection of SHR-3045 in 16 healthy adults to see if it is safe and how the body processes it. The drug is being developed as a potential treatment for rheumatoid arthritis, an autoimmune disease that causes joint pain and swelling. Because this…

This early-stage trial tested the safety of a new drug called SHR-3045 in 40 healthy adults. The study was randomized, double-blind, and placebo-controlled, meaning some participants got the drug and some got a dummy shot. The main goal was to see if the drug causes any side effe…

This early-stage trial tests a new drug called SHR-1139 in healthy volunteers and people with moderate-to-severe plaque psoriasis. The main goal is to check safety and how the body handles the drug. A total of 64 participants will receive either the drug or a placebo, with doses …

This study tested a single injection of a new drug called SHR-1905 in 9 teenagers with asthma. The goal was to see how the drug moves through the body, if it is safe, and if it helps control asthma. Participants were aged 12 to 17, had asthma for at least 6 months, and were on st…

This early-stage study tested an experimental drug called SHR-2173 in 30 adults with systemic lupus erythematosus (SLE). The drug was given as multiple injections under the skin. The main goal was to see if it is safe and tolerable, and to measure how the body processes it. This …

This early-stage trial tested an experimental drug called SHR-4597, given as an inhaled powder, in 62 healthy volunteers and people with asthma. The main goal was to see if it is safe and tolerable. The study gave single doses to healthy people and multiple doses over several day…

This study tested an experimental drug called HRS-2261 in 97 adults with refractory chronic cough—a persistent cough that doesn't respond to usual treatments. Participants took the drug or a placebo for 4 weeks to see if it reduced cough severity and improved quality of life. The…

This early-stage study tested a new drug, SHR-2106, in 52 healthy adults to see if it is safe and how the body processes it. Participants received a single dose either through a vein or under the skin. The goal was not to treat any disease, but to gather important safety informat…